메뉴 건너뛰기




Volumn 33, Issue 2-3, 2014, Pages 399-411

AR function in promoting metastatic prostate cancer

Author keywords

Androgen; Androgen receptor (AR); Castration resistant prostate cancer, CRPC; Cistrome; Metastasis; Prostate cancer (PCa)

Indexed keywords

ANDROGEN RECEPTOR;

EID: 84905110013     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9471-3     Document Type: Review
Times cited : (70)

References (129)
  • 2
    • 57849151139 scopus 로고    scopus 로고
    • Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?
    • Klein, E. A., Ciezki, J., Kupelian, P. A., & Mahadevan, A. (2009). Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urologic Oncology, 27, 67-71.
    • (2009) Urologic Oncology , vol.27 , pp. 67-71
    • Klein, E.A.1    Ciezki, J.2    Kupelian, P.A.3    Mahadevan, A.4
  • 4
    • 68049140791 scopus 로고    scopus 로고
    • Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer
    • Knudsen, K. E., & Scher, H. I. (2009). Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clinical Cancer Research, 15, 4792-4798.
    • (2009) Clinical Cancer Research , vol.15 , pp. 4792-4798
    • Knudsen, K.E.1    Scher, H.I.2
  • 6
    • 45849138558 scopus 로고    scopus 로고
    • Hormonal approaches in prostate cancer: Application in the contemporary prostate cancer patient
    • DOI 10.1016/j.urolonc.2007.11.003, PII S1078143907002608
    • Beekman, K. W., & Hussain, M. (2008). Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient. Urologic Oncology, 26, 415-419. (Pubitemid 351885377)
    • (2008) Urologic Oncology: Seminars and Original Investigations , vol.26 , Issue.4 , pp. 415-419
    • Beekman, K.W.1    Hussain, M.2
  • 7
    • 33644698567 scopus 로고    scopus 로고
    • Management of advanced prostate cancer after first-line chemotherapy
    • DOI 10.1200/JCO.2005.03.1435
    • Berthold, D. R., Sternberg, C. N., & Tannock, I. F. (2005). Management of advanced prostate cancer after first-line chemotherapy. Journal of Clinical Oncology, 23, 8247-8252. (Pubitemid 46211562)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.32 , pp. 8247-8252
    • Berthold, D.R.1    Sternberg, C.N.2    Tannock, I.F.3
  • 8
    • 0032761807 scopus 로고    scopus 로고
    • Chemotherapy for advanced hormone refractory prostate cancer
    • Petrylak, D. P. (1999). Chemotherapy for advanced hormone refractory prostate cancer. Urology, 54, 30-35.
    • (1999) Urology , vol.54 , pp. 30-35
    • Petrylak, D.P.1
  • 9
    • 33746021720 scopus 로고    scopus 로고
    • Chemotherapy for advanced prostate cancer: Docetaxel and beyond
    • Dreicer, R. (2006). Chemotherapy for advanced prostate cancer: docetaxel and beyond. Hematology/Oncology Clinics of North America, 20, 935-946. x.
    • (2006) Hematology/Oncology Clinics of North America , vol.20
    • Dreicer, R.1
  • 10
    • 77952554163 scopus 로고    scopus 로고
    • Partners in crime: Deregulation of AR activity and androgen synthesis in prostate cancer
    • Knudsen, K. E., & Penning, T. M. (2010). Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism, 21, 315-324.
    • (2010) Trends in Endocrinology and Metabolism , vol.21 , pp. 315-324
    • Knudsen, K.E.1    Penning, T.M.2
  • 11
    • 42949134229 scopus 로고    scopus 로고
    • Maximal androgen blockade for the treatment of metastatic prostate cancer - A systematic review
    • Lukka, H., Waldron, T., Klotz, L., Winquist, E., & Trachtenberg, J. (2006). Maximal androgen blockade for the treatment of metastatic prostate cancer - a systematic review. Current Oncology, 13, 81-93.
    • (2006) Current Oncology , vol.13 , pp. 81-93
    • Lukka, H.1    Waldron, T.2    Klotz, L.3    Winquist, E.4    Trachtenberg, J.5
  • 12
    • 58049196759 scopus 로고    scopus 로고
    • Mechanisms mediating androgen receptor reactivation after castration
    • Yuan, X., & Balk, S. P. (2009). Mechanisms mediating androgen receptor reactivation after castration. Urologic Oncology, 27, 36-41.
    • (2009) Urologic Oncology , vol.27 , pp. 36-41
    • Yuan, X.1    Balk, S.P.2
  • 13
    • 84901827161 scopus 로고    scopus 로고
    • Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
    • doi:10.1038/onc.2013.235
    • Yuan, X., Cai, C., Chen, S., Yu, Z., & Balk, S. P. (2013). Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. doi:10.1038/onc.2013.235.
    • (2013) Oncogene
    • Yuan, X.1    Cai, C.2    Chen, S.3    Yu, Z.4    Balk, S.P.5
  • 14
    • 84856927346 scopus 로고    scopus 로고
    • Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    • Dennis, E. R., Jia, X., Mezheritskiy, I. S., et al. (2012). Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. Journal of Clinical Oncology, 30, 519-524.
    • (2012) Journal of Clinical Oncology , vol.30 , pp. 519-524
    • Dennis, E.R.1    Jia, X.2    Mezheritskiy, I.S.3
  • 18
    • 0034714276 scopus 로고    scopus 로고
    • Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations
    • Matias, P. M., Donner, P., Coelho, R., et al. (2000). Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. Journal of Biological Chemistry, 275, 26164-26171.
    • (2000) Journal of Biological Chemistry , vol.275 , pp. 26164-26171
    • Matias, P.M.1    Donner, P.2    Coelho, R.3
  • 20
    • 55049086227 scopus 로고    scopus 로고
    • The contribution of different androgen receptor domains to receptor dimerization and signaling
    • Centenera, M. M., Harris, J. M., Tilley, W. D., & Butler, L. M. (2008). The contribution of different androgen receptor domains to receptor dimerization and signaling. Molecular Endocrinology, 22, 2373-2382.
    • (2008) Molecular Endocrinology , vol.22 , pp. 2373-2382
    • Centenera, M.M.1    Harris, J.M.2    Tilley, W.D.3    Butler, L.M.4
  • 21
    • 84857360697 scopus 로고    scopus 로고
    • Post-translational modification of the androgen receptor
    • Gioeli, D., & Paschal, B. M. (2012). Post-translational modification of the androgen receptor. Molecular and Cellular Endocrinology, 352, 70-78.
    • (2012) Molecular and Cellular Endocrinology , vol.352 , pp. 70-78
    • Gioeli, D.1    Paschal, B.M.2
  • 22
    • 84869135796 scopus 로고    scopus 로고
    • Regulation of the androgen receptor by post-translational modifications
    • Coffey, K., & Robson, C. N. (2012). Regulation of the androgen receptor by post-translational modifications. Journal of Endocrinology, 215, 221-237.
    • (2012) Journal of Endocrinology , vol.215 , pp. 221-237
    • Coffey, K.1    Robson, C.N.2
  • 24
    • 1042269786 scopus 로고
    • Effect of orchiectomy and irradiation on cancer of the prostate
    • Huggins, C. (1942). Effect of orchiectomy and irradiation on cancer of the prostate. Annals of Surgery, 115, 1192-1200.
    • (1942) Annals of Surgery , vol.115 , pp. 1192-1200
    • Huggins, C.1
  • 25
    • 84894406301 scopus 로고
    • The diagnosis of cancer of the prostate including the interpretation of serum phosphatase values
    • Huggins, C. (1943). The diagnosis of cancer of the prostate including the interpretation of serum phosphatase values. Bulletin of the New York Academy of Medicine, 19, 195-200.
    • (1943) Bulletin of the New York Academy of Medicine , vol.19 , pp. 195-200
    • Huggins, C.1
  • 26
    • 79956135979 scopus 로고
    • The treatment of cancer of the prostate: (The 1943 address in surgery before the Royal College of Physicians and Surgeons of Canada)
    • Huggins, C. (1944). The treatment of cancer of the prostate: (the 1943 address in surgery before the Royal College of Physicians and Surgeons of Canada). Canadian Medical Association Journal, 50, 301-307.
    • (1944) Canadian Medical Association Journal , vol.50 , pp. 301-307
    • Huggins, C.1
  • 27
    • 44649169622 scopus 로고    scopus 로고
    • Testosterone surge: Rationale for gonadotropin-releasing hormone blockers?
    • van Poppel, H., & Nilsson, S. (2008). Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology, 71, 1001-1006.
    • (2008) Urology , vol.71 , pp. 1001-1006
    • Van Poppel, H.1    Nilsson, S.2
  • 28
    • 0034659787 scopus 로고    scopus 로고
    • Hormone therapy for patients with prostate carcinoma
    • Klotz, L. (2000). Hormone therapy for patients with prostate carcinoma. Cancer, 88, 3009-3014.
    • (2000) Cancer , vol.88 , pp. 3009-3014
    • Klotz, L.1
  • 29
    • 0344378213 scopus 로고    scopus 로고
    • Time to normalization of serumtestosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration
    • Oefelein, M. G. (1998). Time to normalization of serumtestosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. Journal of Urology, 160, 1685-1688.
    • (1998) Journal of Urology , vol.160 , pp. 1685-1688
    • Oefelein, M.G.1
  • 30
    • 79956103537 scopus 로고    scopus 로고
    • Outsmarting androgen receptor: Creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
    • Knudsen, K. E., & Kelly, W. K. (2011). Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Review of Endocrinology and Metabolism, 6, 483-493.
    • (2011) Expert Review of Endocrinology and Metabolism , vol.6 , pp. 483-493
    • Knudsen, K.E.1    Kelly, W.K.2
  • 31
    • 80054021222 scopus 로고    scopus 로고
    • Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors
    • Cai, C., Chen, S., Ng, P., et al. (2011). Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Research, 71, 6503-6513.
    • (2011) Cancer Research , vol.71 , pp. 6503-6513
    • Cai, C.1    Chen, S.2    Ng, P.3
  • 32
    • 49249119358 scopus 로고    scopus 로고
    • Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
    • Montgomery, R. B., Mostaghel, E. A., Vessella, R., et al. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research, 68, 4447-4454.
    • (2008) Cancer Research , vol.68 , pp. 4447-4454
    • Montgomery, R.B.1    Mostaghel, E.A.2    Vessella, R.3
  • 33
    • 79953320228 scopus 로고    scopus 로고
    • New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway
    • Attard, G., Richards, J., & de Bono, J. S. (2011). New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clinical Cancer Research, 17, 1649-1657.
    • (2011) Clinical Cancer Research , vol.17 , pp. 1649-1657
    • Attard, G.1    Richards, J.2    De Bono, J.S.3
  • 34
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • de Bono, J. S., Logothetis, C. J., Molina, A., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364, 1995-2005.
    • (2011) New England Journal of Medicine , vol.364 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 35
    • 84863393126 scopus 로고    scopus 로고
    • Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
    • Efstathiou, E., Titus, M., Tsavachidou, D., et al. (2012). Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. Journal of Clinical Oncology, 30, 637-643.
    • (2012) Journal of Clinical Oncology , vol.30 , pp. 637-643
    • Efstathiou, E.1    Titus, M.2    Tsavachidou, D.3
  • 36
    • 84883741726 scopus 로고    scopus 로고
    • Overview of the latest treatments for castration-resistant prostate cancer
    • Bishr, M., & Saad, F. (2013). Overview of the latest treatments for castration-resistant prostate cancer. Nature Reviews. Urology, 10(9), 522-528.
    • (2013) Nature Reviews. Urology , vol.10 , Issue.9 , pp. 522-528
    • Bishr, M.1    Saad, F.2
  • 37
    • 79959233647 scopus 로고    scopus 로고
    • Targeting continued androgen receptor signaling in prostate cancer
    • Massard, C., & Fizazi, K. (2011). Targeting continued androgen receptor signaling in prostate cancer. Clinical Cancer Research, 17, 3876-3883.
    • (2011) Clinical Cancer Research , vol.17 , pp. 3876-3883
    • Massard, C.1    Fizazi, K.2
  • 38
    • 84866948935 scopus 로고    scopus 로고
    • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    • Fizazi, K., Scher, H. I., Molina, A., et al. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, 13, 983-992.
    • (2012) Lancet Oncology , vol.13 , pp. 983-992
    • Fizazi, K.1    Scher, H.I.2    Molina, A.3
  • 39
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367, 1187-1197.
    • (2012) New England Journal of Medicine , vol.367 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 40
    • 84881529561 scopus 로고    scopus 로고
    • Enzalutamide: A novel anti-androgen with prolonged survival rate in CRPC patients
    • Dhingra, R., Sharma, T., Singh, S., et al. (2013). Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients. Mini Reviews Medicinal Chemistry, 13, 1475-1486.
    • (2013) Mini Reviews Medicinal Chemistry , vol.13 , pp. 1475-1486
    • Dhingra, R.1    Sharma, T.2    Singh, S.3
  • 41
    • 79959282824 scopus 로고    scopus 로고
    • Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients
    • Attard, G., & de Bono, J. S. (2011). Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clinical Cancer Research, 17, 3867-3875.
    • (2011) Clinical Cancer Research , vol.17 , pp. 3867-3875
    • Attard, G.1    De Bono, J.S.2
  • 42
    • 84883402878 scopus 로고    scopus 로고
    • Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
    • Bahl, A., Oudard, S., Tombal, B., et al. (2013). Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Annals of Oncology, 24(9), 2402-8.
    • (2013) Annals of Oncology , vol.24 , Issue.9 , pp. 2402-2408
    • Bahl, A.1    Oudard, S.2    Tombal, B.3
  • 43
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
    • de Bono, J. S., Oudard, S., Ozguroglu, M., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376, 1147-1154.
    • (2010) Lancet , vol.376 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 44
    • 0033822572 scopus 로고    scopus 로고
    • Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline
    • Berruti, A., Dogliotti, L., Bitossi, R., et al. (2000). Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. Journal of Urology, 164, 1248-1253.
    • (2000) Journal of Urology , vol.164 , pp. 1248-1253
    • Berruti, A.1    Dogliotti, L.2    Bitossi, R.3
  • 46
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • Parker, C., Nilsson, S., Heinrich, D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 369, 213-223.
    • (2013) New England Journal of Medicine , vol.369 , pp. 213-223
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 48
    • 78449300594 scopus 로고    scopus 로고
    • CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
    • Sun, X., Cheng, G., Hao, M., et al. (2010). CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer and Metastasis Reviews, 29, 709-722.
    • (2010) Cancer and Metastasis Reviews , vol.29 , pp. 709-722
    • Sun, X.1    Cheng, G.2    Hao, M.3
  • 50
    • 69449096661 scopus 로고    scopus 로고
    • Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro
    • Frigo, D. E., Sherk, A. B., Wittmann, B. M., et al. (2009). Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Molecular Endocrinology, 23, 1385-1396.
    • (2009) Molecular Endocrinology , vol.23 , pp. 1385-1396
    • Frigo, D.E.1    Sherk, A.B.2    Wittmann, B.M.3
  • 51
    • 3142666166 scopus 로고    scopus 로고
    • CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells
    • DOI 10.1158/0008-5472.CAN-03-3437
    • Shulby, S. A., Dolloff, N. G., Stearns, M. E., Meucci, O., & Fatatis, A. (2004). CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Research, 64, 4693-4698. (Pubitemid 38924507)
    • (2004) Cancer Research , vol.64 , Issue.14 , pp. 4693-4698
    • Shulby, S.A.1    Dolloff, N.G.2    Stearns, M.E.3    Meucci, O.4    Fatatis, A.5
  • 52
    • 0033568470 scopus 로고    scopus 로고
    • Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4
    • DOI 10.1006/dbio.1999.9405
    • McGrath, K. E., Koniski, A. D., Maltby, K. M., McGann, J. K.,&Palis, J. (1999). Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Developmental Biology, 213, 442-456. (Pubitemid 29444352)
    • (1999) Developmental Biology , vol.213 , Issue.2 , pp. 442-456
    • McGrath, K.E.1    Koniski, A.D.2    Maltby, K.M.3    McGann, J.K.4    Palis, J.5
  • 54
    • 19944433608 scopus 로고    scopus 로고
    • Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo
    • Sun, Y. X., Schneider, A., Jung, Y., et al. (2005). Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research, 20, 318-329.
    • (2005) Journal of Bone and Mineral Research , vol.20 , pp. 318-329
    • Sun, Y.X.1    Schneider, A.2    Jung, Y.3
  • 55
    • 67650758019 scopus 로고    scopus 로고
    • Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer
    • Wang, Q., Li, W., Zhang, Y., et al. (2009). Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138, 245-256.
    • (2009) Cell , vol.138 , pp. 245-256
    • Wang, Q.1    Li, W.2    Zhang, Y.3
  • 56
    • 79960071366 scopus 로고    scopus 로고
    • The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
    • Massie, C. E., Lynch, A., Ramos-Montoya, A., et al. (2011). The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal, 30, 2719-2733.
    • (2011) EMBO Journal , vol.30 , pp. 2719-2733
    • Massie, C.E.1    Lynch, A.2    Ramos-Montoya, A.3
  • 57
    • 84882285291 scopus 로고    scopus 로고
    • ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
    • Chen, Y., Chi, P., Rockowitz, S., et al. (2013). ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine, 19, 1023-1029.
    • (2013) Nature Medicine , vol.19 , pp. 1023-1029
    • Chen, Y.1    Chi, P.2    Rockowitz, S.3
  • 59
    • 40949139389 scopus 로고    scopus 로고
    • CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: Potential role in prostate cancer bone tropism
    • DOI 10.1158/0008-5472.CAN-07-1315
    • Jamieson, W. L., Shimizu, S., D'Ambrosio, J. A., Meucci, O., & Fatatis, A. (2008). CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Research, 68, 1715-1722. (Pubitemid 351416556)
    • (2008) Cancer Research , vol.68 , Issue.6 , pp. 1715-1722
    • Jamieson, W.L.1    Shimizu, S.2    D'Ambrosio, J.A.3    Meucci, O.4    Fatatis, A.5
  • 60
    • 0032547581 scopus 로고    scopus 로고
    • 3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow
    • DOI 10.1084/jem.188.8.1413
    • Fong, A. M., Robinson, L. A., Steeber, D. A., et al. (1998). Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. Journal of Experimental Medicine, 188, 1413-1419. (Pubitemid 28489578)
    • (1998) Journal of Experimental Medicine , vol.188 , Issue.8 , pp. 1413-1419
    • Fong, A.M.1    Robinson, L.A.2    Steeber, D.A.3    Tedder, T.F.4    Yoshie, O.5    Imai, T.6    Patel, D.D.7
  • 63
    • 40849085514 scopus 로고    scopus 로고
    • FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
    • DOI 10.1016/j.cell.2008.01.018, PII S0092867408001189
    • Lupien, M., Eeckhoute, J., Meyer, C. A., et al. (2008). FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell, 132, 958-970. (Pubitemid 351391952)
    • (2008) Cell , vol.132 , Issue.6 , pp. 958-970
    • Lupien, M.1    Eeckhoute, J.2    Meyer, C.A.3    Wang, Q.4    Zhang, Y.5    Li, W.6    Carroll, J.S.7    Liu, X.S.8    Brown, M.9
  • 64
    • 67650480389 scopus 로고    scopus 로고
    • Cistromics of hormone-dependent cancer
    • Lupien, M., & Brown, M. (2009). Cistromics of hormone-dependent cancer. Endocrine-Related Cancer, 16, 381-389.
    • (2009) Endocrine-Related Cancer , vol.16 , pp. 381-389
    • Lupien, M.1    Brown, M.2
  • 65
    • 79953319002 scopus 로고    scopus 로고
    • Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers
    • Serandour, A. A., Avner, S., Percevault, F., et al. (2011). Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Research, 21, 555-565.
    • (2011) Genome Research , vol.21 , pp. 555-565
    • Serandour, A.A.1    Avner, S.2    Percevault, F.3
  • 66
    • 67649208317 scopus 로고    scopus 로고
    • Coactivator function defines the active estrogen receptor alpha cistrome
    • Lupien, M., Eeckhoute, J., Meyer, C. A., et al. (2009). Coactivator function defines the active estrogen receptor alpha cistrome. Molecular and Cellular Biology, 29, 3413-3423.
    • (2009) Molecular and Cellular Biology , vol.29 , pp. 3413-3423
    • Lupien, M.1    Eeckhoute, J.2    Meyer, C.A.3
  • 67
    • 84874507326 scopus 로고    scopus 로고
    • FoxA1 is a key mediator of hormonal response in breast and prostate cancer
    • Robinson, J. L., & Carroll, J. S. (2012). FoxA1 is a key mediator of hormonal response in breast and prostate cancer. Frontiers Endocrinology (Lausanne), 3, 68.
    • (2012) Frontiers Endocrinology (Lausanne) , vol.3 , pp. 68
    • Robinson, J.L.1    Carroll, J.S.2
  • 68
    • 84874918445 scopus 로고    scopus 로고
    • FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells
    • Sahu, B., Laakso, M., Pihlajamaa, P., et al. (2013). FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Research, 73, 1570-1580.
    • (2013) Cancer Research , vol.73 , pp. 1570-1580
    • Sahu, B.1    Laakso, M.2    Pihlajamaa, P.3
  • 69
    • 80053610846 scopus 로고    scopus 로고
    • Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer
    • Sahu, B., Laakso, M., Ovaska, K., et al. (2011). Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO Journal, 30, 3962-3976.
    • (2011) EMBO Journal , vol.30 , pp. 3962-3976
    • Sahu, B.1    Laakso, M.2    Ovaska, K.3
  • 70
    • 80053611688 scopus 로고    scopus 로고
    • FOXA1: Master of steroid receptor function in cancer
    • Augello, M. A., Hickey, T. E., & Knudsen, K. E. (2011). FOXA1: master of steroid receptor function in cancer. EMBO Journal, 30, 3885-3894.
    • (2011) EMBO Journal , vol.30 , pp. 3885-3894
    • Augello, M.A.1    Hickey, T.E.2    Knudsen, K.E.3
  • 71
    • 80155126691 scopus 로고    scopus 로고
    • Definition of a FoxA1 cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer
    • Zhang, C., Wang, L., Wu, D., et al. (2011). Definition of a FoxA1 cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Research, 71, 6738-6748.
    • (2011) Cancer Research , vol.71 , pp. 6738-6748
    • Zhang, C.1    Wang, L.2    Wu, D.3
  • 72
    • 84855987529 scopus 로고    scopus 로고
    • FOXA1 promotes tumor progression in prostate cancer and represents a novel hall-mark of castration-resistant prostate cancer
    • Gerhardt, J., Montani, M., Wild, P., et al. (2012). FOXA1 promotes tumor progression in prostate cancer and represents a novel hall-mark of castration-resistant prostate cancer. American Journal of Pathology, 180, 848-861.
    • (2012) American Journal of Pathology , vol.180 , pp. 848-861
    • Gerhardt, J.1    Montani, M.2    Wild, P.3
  • 73
    • 84879085247 scopus 로고    scopus 로고
    • Androgen receptor-independent function of FoxA1 in prostate cancer metastasis
    • Jin, H. J., Zhao, J. C., Ogden, I., Bergan, R. C., & Yu, J. (2013). Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Research, 73, 3725-3736.
    • (2013) Cancer Research , vol.73 , pp. 3725-3736
    • Jin, H.J.1    Zhao, J.C.2    Ogden, I.3    Bergan, R.C.4    Yu, J.5
  • 74
    • 79954568222 scopus 로고    scopus 로고
    • High-level expression of forkhead-box protein A1 in metastatic prostate cancer
    • Jain, R. K., Mehta, R. J., Nakshatri, H., Idrees, M. T.,& Badve, S. S. (2011). High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology, 58, 766-772.
    • (2011) Histopathology , vol.58 , pp. 766-772
    • Jain, R.K.1    Mehta, R.J.2    Nakshatri, H.3    Idrees, M.T.4    Badve, S.S.5
  • 75
    • 84863723010 scopus 로고    scopus 로고
    • The mutational landscape of lethal castration-resistant prostate cancer
    • Grasso, C. S., Wu, Y. M., Robinson, D. R., et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature, 487, 239-243.
    • (2012) Nature , vol.487 , pp. 239-243
    • Grasso, C.S.1    Wu, Y.M.2    Robinson, D.R.3
  • 76
    • 84861581164 scopus 로고    scopus 로고
    • Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
    • Barbieri, C. E., Baca, S. C., Lawrence, M. S., et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics, 44, 685-689.
    • (2012) Nature Genetics , vol.44 , pp. 685-689
    • Barbieri, C.E.1    Baca, S.C.2    Lawrence, M.S.3
  • 78
    • 84555204370 scopus 로고    scopus 로고
    • Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer
    • Wu, J. I. (2012). Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer. Acta Biochimica Biophysica Sinica (Shanghai), 44, 54-69.
    • (2012) Acta Biochimica Biophysica Sinica (Shanghai) , vol.44 , pp. 54-69
    • Wu, J.I.1
  • 79
    • 70350539592 scopus 로고    scopus 로고
    • Hijacking the chromatin remodeling machinery: Impact of SWI/SNF perturbations in cancer
    • Weissman, B., & Knudsen, K. E. (2009). Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Research, 69, 8223-8230.
    • (2009) Cancer Research , vol.69 , pp. 8223-8230
    • Weissman, B.1    Knudsen, K.E.2
  • 80
    • 58249086425 scopus 로고    scopus 로고
    • Understanding the words of chromatin regulation
    • Wu, J. I., Lessard, J., & Crabtree, G. R. (2009). Understanding the words of chromatin regulation. Cell, 136, 200-206.
    • (2009) Cell , vol.136 , pp. 200-206
    • Wu, J.I.1    Lessard, J.2    Crabtree, G.R.3
  • 81
    • 49649117206 scopus 로고    scopus 로고
    • Targeting the BAF57 SWI/SNF subunit in prostate cancer: A novel platform to control androgen receptor activity
    • Link, K. A., Balasubramaniam, S., Sharma, A., et al. (2008). Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Research, 68, 4551-4558.
    • (2008) Cancer Research , vol.68 , pp. 4551-4558
    • Link, K.A.1    Balasubramaniam, S.2    Sharma, A.3
  • 82
    • 84878042268 scopus 로고    scopus 로고
    • Aberrant BAF57 signaling facilitates prometastatic phenotypes
    • Balasubramaniam, S., Comstock, C. E., Ertel, A., et al. (2013). Aberrant BAF57 signaling facilitates prometastatic phenotypes. Clinical Cancer Research, 19, 2657-2667.
    • (2013) Clinical Cancer Research , vol.19 , pp. 2657-2667
    • Balasubramaniam, S.1    Comstock, C.E.2    Ertel, A.3
  • 84
    • 33845394286 scopus 로고    scopus 로고
    • The cyclin D1b splice variant: An old oncogene learns new tricks
    • Knudsen, K. E. (2006). The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Division, 1, 15.
    • (2006) Cell Division , vol.1 , pp. 15
    • Knudsen, K.E.1
  • 85
    • 0242526150 scopus 로고    scopus 로고
    • An Alternatively Spliced Cyclin D1 Isoform, Cyclin D1b, Is a Nuclear Oncogene
    • Lu, F., Gladden, A. B., & Diehl, J. A. (2003). An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Research, 63, 7056-7061. (Pubitemid 37413439)
    • (2003) Cancer Research , vol.63 , Issue.21 , pp. 7056-7061
    • Lu, F.1    Gladden, A.B.2    Diehl, J.A.3
  • 86
    • 70349912696 scopus 로고    scopus 로고
    • Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells
    • Kim, C. J., Nishi, K., Isono, T., et al. (2009). Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells. Molecular Carcinogenesis, 48, 953-964.
    • (2009) Molecular Carcinogenesis , vol.48 , pp. 953-964
    • Kim, C.J.1    Nishi, K.2    Isono, T.3
  • 87
    • 48649103464 scopus 로고    scopus 로고
    • Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists
    • Wang, Y., Dean, J. L., Millar, E. K., et al. (2008). Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Research, 68, 5628-5638.
    • (2008) Cancer Research , vol.68 , pp. 5628-5638
    • Wang, Y.1    Dean, J.L.2    Millar, E.K.3
  • 88
    • 14844333265 scopus 로고    scopus 로고
    • 2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression
    • DOI 10.1210/me.2004-0266
    • Burd, C. J., Petre, C. E., Moghadam, H., Wilson, E. M., & Knudsen, K. E. (2005). Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles forAR corepression. Molecular Endocrinology, 19, 607-620. (Pubitemid 40349435)
    • (2005) Molecular Endocrinology , vol.19 , Issue.3 , pp. 607-620
    • Burd, C.J.1    Petre, C.E.2    Moghadam, H.3    Wilson, E.M.4    Knudsen, K.E.5
  • 89
    • 79953153894 scopus 로고    scopus 로고
    • Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function
    • Comstock, C. E., Augello, M. A., Schiewer, M. J., et al. (2011). Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. Journal of Biological Chemistry, 286, 8117-8127.
    • (2011) Journal of Biological Chemistry , vol.286 , pp. 8117-8127
    • Comstock, C.E.1    Augello, M.A.2    Schiewer, M.J.3
  • 90
    • 0037127320 scopus 로고    scopus 로고
    • Cyclin D1: Mechanism and consequence of androgen receptor co-repressor activity
    • DOI 10.1074/jbc.M106399200
    • Petre, C. E., Wetherill, Y. B., Danielsen, M., & Knudsen, K. E. (2002). Cyclin D1: mechanism and consequence of androgen receptor corepressor activity. Journal of Biological Chemistry, 277, 2207-2215. (Pubitemid 34968808)
    • (2002) Journal of Biological Chemistry , vol.277 , Issue.3 , pp. 2207-2215
    • Petre, C.E.1    Wetherill, Y.B.2    Danielsen, M.3    Knudsen, K.E.4
  • 93
    • 33645118564 scopus 로고    scopus 로고
    • Cyclin D1: Polymorphism, aberrant splicing and cancer risk
    • Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006). Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 25, 1620-1628.
    • (2006) Oncogene , vol.25 , pp. 1620-1628
    • Knudsen, K.E.1    Diehl, J.A.2    Haiman, C.A.3    Knudsen, E.S.4
  • 94
    • 84873872188 scopus 로고    scopus 로고
    • Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes
    • Augello, M. A., Burd, C. J., Birbe, R., et al. (2013). Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. Journal of Clinical Investigation, 123, 493-508.
    • (2013) Journal of Clinical Investigation , vol.123 , pp. 493-508
    • Augello, M.A.1    Burd, C.J.2    Birbe, R.3
  • 95
    • 77954637769 scopus 로고    scopus 로고
    • Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines
    • Emadi Baygi, M., Soheili, Z. S., Essmann, F., et al. (2010). Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biology, 31, 297-307.
    • (2010) Tumour Biology , vol.31 , pp. 297-307
    • Emadi Baygi, M.1    Soheili, Z.S.2    Essmann, F.3
  • 96
    • 84865582502 scopus 로고    scopus 로고
    • Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer
    • Wu, K., Gore, C., Yang, L., et al. (2012). Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Molecular Endocrinology, 26, 1496-1507.
    • (2012) Molecular Endocrinology , vol.26 , pp. 1496-1507
    • Wu, K.1    Gore, C.2    Yang, L.3
  • 97
    • 84905110156 scopus 로고    scopus 로고
    • Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
    • Chicago, IL: Journal of Clinical Oncology; p. Abstract 4655
    • Kelly WK HS, Carducci MA, et al. (2012). Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). 2012 ASCO Annual Meeting. Chicago, IL: Journal of Clinical Oncology; p. Abstract 4655.
    • (2012) 2012 ASCO Annual Meeting
    • Kelly, W.K.H.S.1    Carducci, M.A.2
  • 98
    • 35648948853 scopus 로고    scopus 로고
    • TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer: Clinical and Biologic Implications
    • DOI 10.1016/j.urology.2007.08.032, PII S0090429507020146
    • Barry, M., Perner, S., Demichelis, F., & Rubin, M. A. (2007). TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology, 70, 630-633. (Pubitemid 350030260)
    • (2007) Urology , vol.70 , Issue.4 , pp. 630-633
    • Barry, M.1    Perner, S.2    Demichelis, F.3    Rubin, M.A.4
  • 99
    • 79951497419 scopus 로고    scopus 로고
    • The genomic complexity of primary human prostate cancer
    • Berger, M. F., Lawrence, M. S., Demichelis, F., et al. (2011). The genomic complexity of primary human prostate cancer. Nature, 470, 214-220.
    • (2011) Nature , vol.470 , pp. 214-220
    • Berger, M.F.1    Lawrence, M.S.2    Demichelis, F.3
  • 101
    • 68049101459 scopus 로고    scopus 로고
    • Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States
    • Mosquera, J. M., Mehra, R., Regan, M. M., et al. (2009). Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clinical Cancer Research, 15, 4706-4711.
    • (2009) Clinical Cancer Research , vol.15 , pp. 4706-4711
    • Mosquera, J.M.1    Mehra, R.2    Regan, M.M.3
  • 102
    • 67649425225 scopus 로고    scopus 로고
    • ETS gene fusions in prostate cancer: From discovery to daily clinical practice
    • Tomlins, S. A., Bjartell, A., Chinnaiyan, A. M., et al. (2009). ETS gene fusions in prostate cancer: from discovery to daily clinical practice. European Urology, 56, 275-286.
    • (2009) European Urology , vol.56 , pp. 275-286
    • Tomlins, S.A.1    Bjartell, A.2    Chinnaiyan, A.M.3
  • 104
    • 84873607610 scopus 로고    scopus 로고
    • Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer
    • Weischenfeldt, J., Simon, R., Feuerbach, L., et al. (2013). Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell, 23, 159-170.
    • (2013) Cancer Cell , vol.23 , pp. 159-170
    • Weischenfeldt, J.1    Simon, R.2    Feuerbach, L.3
  • 107
    • 70849135782 scopus 로고    scopus 로고
    • Induced chromosomal proximity and gene fusions in prostate cancer
    • Mani, R. S., Tomlins, S. A., Callahan, K., et al. (2009). Induced chromosomal proximity and gene fusions in prostate cancer. Science, 326, 1230.
    • (2009) Science , vol.326 , pp. 1230
    • Mani, R.S.1    Tomlins, S.A.2    Callahan, K.3
  • 108
    • 71249101060 scopus 로고    scopus 로고
    • Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer
    • Lin, C., Yang, L., Tanasa, B., et al. (2009). Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell, 139, 1069-1083.
    • (2009) Cell , vol.139 , pp. 1069-1083
    • Lin, C.1    Yang, L.2    Tanasa, B.3
  • 111
    • 66749100105 scopus 로고    scopus 로고
    • Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
    • King, J. C., Xu, J., Wongvipat, J., et al. (2009). Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genetics, 41, 524-526.
    • (2009) Nature Genetics , vol.41 , pp. 524-526
    • King, J.C.1    Xu, J.2    Wongvipat, J.3
  • 112
    • 77952103123 scopus 로고    scopus 로고
    • An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression
    • Yu, J., Mani, R. S., Cao, Q., et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell, 17, 443-454.
    • (2010) Cancer Cell , vol.17 , pp. 443-454
    • Yu, J.1    Mani, R.S.2    Cao, Q.3
  • 113
    • 18644382388 scopus 로고    scopus 로고
    • The polycomb group protein EZH2 is involved in progression of prostate cancer
    • Varambally, S., Dhanasekaran, S. M., Zhou, M., et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-629.
    • (2002) Nature , vol.419 , pp. 624-629
    • Varambally, S.1    Dhanasekaran, S.M.2    Zhou, M.3
  • 115
    • 84871052080 scopus 로고    scopus 로고
    • EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent
    • Xu, K., Wu, Z. J., Groner, A. C., et al. (2012). EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science, 338, 1465-1469.
    • (2012) Science , vol.338 , pp. 1465-1469
    • Xu, K.1    Wu, Z.J.2    Groner, A.C.3
  • 116
    • 0036696817 scopus 로고    scopus 로고
    • Twenty pairs of sox: Extent, homology, and nomenclature of the mouse and human sox transcription factor gene families
    • Schepers, G. E., Teasdale, R. D.,&Koopman, P. (2002). Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Developmental Cell, 3, 167-170.
    • (2002) Developmental Cell , vol.3 , pp. 167-170
    • Schepers, G.E.1    Teasdale, R.D.2    Koopman, P.3
  • 119
    • 84865277434 scopus 로고    scopus 로고
    • A Sox9/Fgf feed-forward loop maintains pancreatic organ identity
    • Seymour, P. A., Shih, H. P., Patel, N. A., et al. (2012). A Sox9/Fgf feed-forward loop maintains pancreatic organ identity. Development, 139, 3363-3372.
    • (2012) Development , vol.139 , pp. 3363-3372
    • Seymour, P.A.1    Shih, H.P.2    Patel, N.A.3
  • 120
    • 78651228289 scopus 로고    scopus 로고
    • Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine
    • Furuyama, K., Kawaguchi, Y., Akiyama, H., et al. (2011). Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nature Genetics, 43, 34-41.
    • (2011) Nature Genetics , vol.43 , pp. 34-41
    • Furuyama, K.1    Kawaguchi, Y.2    Akiyama, H.3
  • 122
    • 76249098305 scopus 로고    scopus 로고
    • SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation
    • Thomsen, M. K., Ambroisine, L., Wynn, S., et al. (2010). SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Research, 70, 979-987.
    • (2010) Cancer Research , vol.70 , pp. 979-987
    • Thomsen, M.K.1    Ambroisine, L.2    Wynn, S.3
  • 123
    • 40949145618 scopus 로고    scopus 로고
    • SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion
    • DOI 10.1158/0008-5472.CAN-07-5915
    • Wang, H., Leav, I., Ibaragi, S., et al. (2008). SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Research, 68, 1625-1630. (Pubitemid 351416545)
    • (2008) Cancer Research , vol.68 , Issue.6 , pp. 1625-1630
    • Wang, H.1    Leav, I.2    Ibaragi, S.3    Wegner, M.4    Hu, G.-F.5    Lu, M.L.6    Balk, S.P.7    Yuan, X.8
  • 124
    • 84874598190 scopus 로고    scopus 로고
    • ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer
    • Cai, C., Wang, H., He, H. H., et al. (2013). ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. Journal of Clinical Investigation, 123, 1109-1122.
    • (2013) Journal of Clinical Investigation , vol.123 , pp. 1109-1122
    • Cai, C.1    Wang, H.2    He, H.H.3
  • 125
    • 79953099043 scopus 로고    scopus 로고
    • Immunotherapy in castration-resistant prostate cancer: Integrating sipuleucel-T into our current treatment paradigm
    • Garcia, J. A., & Dreicer, R. (2011). Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Oncology (Williston Park), 25, 242-249.
    • (2011) Oncology (Williston Park) , vol.25 , pp. 242-249
    • Garcia, J.A.1    Dreicer, R.2
  • 126
    • 34548740289 scopus 로고    scopus 로고
    • Neoadjuvant docetaxel treatment for locally advanced prostate cancer: A clinicopathologic study
    • DOI 10.1002/cncr.22897
    • Magi-Galluzzi, C., Zhou, M., Reuther, A. M., Dreicer, R., & Klein, E. A. (2007). Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer, 110, 1248-1254. (Pubitemid 47435595)
    • (2007) Cancer , vol.110 , Issue.6 , pp. 1248-1254
    • Magi-Galluzzi, C.1    Zhou, M.2    Reuther, A.M.3    Dreicer, R.4    Klein, E.A.5
  • 127
    • 78649523986 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study
    • abstr 3084 2010.
    • Dreicer, R., Agus, D. B., MacVicar, G. R., Wang, J., MacLean, D., & Stadler, W. M. (2010). Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study. Journal of Clinical Oncology, 28, 15s. (suppl; abstr 3084) 2010.
    • (2010) Journal of Clinical Oncology , vol.28 , Issue.SUPPL.
    • Dreicer, R.1    Agus, D.B.2    MacVicar, G.R.3    Wang, J.4    MacLean, D.5    Stadler, W.M.6
  • 128
    • 84872078210 scopus 로고    scopus 로고
    • Abiraterone in metastatic prostate cancer without previous chemotherapy
    • Ryan, C. J., Smith, M. R., de Bono, J. S., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine, 368, 138-148.
    • (2013) New England Journal of Medicine , vol.368 , pp. 138-148
    • Ryan, C.J.1    Smith, M.R.2    De Bono, J.S.3
  • 129
    • 79952734485 scopus 로고    scopus 로고
    • A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
    • Pacey, S., Wilson, R. H., Walton, M., et al. (2011). A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clinical Cancer Research, 17, 1561-1570.
    • (2011) Clinical Cancer Research , vol.17 , pp. 1561-1570
    • Pacey, S.1    Wilson, R.H.2    Walton, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.